| Symbol | RNAC |
|---|---|
| Name | CARTESIAN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 65 GROVE STREET, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | +1 617 923-1400 |
| Fax | — |
| — | |
| Website | https://www.cartesiantherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001453687 |
| Description | Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity. Additional info from NASDAQ: |
(99% Neutral) CARTESIAN THERAPEUTICS, INC. (RNAC) Announces Regulatory Update
Read more(10% Negative) CARTESIAN THERAPEUTICS, INC. (RNAC) Announces Delay in expected Trials for autoimmune diseases Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Read more📋 MILOS MILJKOVIC (Ex-Affiliate) plans to sell 4K shares of CARTESIAN THERAPEUTICS, INC. (at $6.41 each, total $25K) Filed: Jun 02, 2026 | ID: 005471
Read more(10% Negative) CARTESIAN THERAPEUTICS, INC. (RNAC) Announces Delay in expected Trials for autoimmune diseases Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Read moreCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07391605 | Descartes-08 in Autoantibody Myositis | Phase2 | Antisynthetase Syndrome | Recruiting | 2026-04-28 | 2028-05-01 | ClinicalTrials.gov |
| NCT07089121 | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disord… | Phase1 | Childhood-onset Systemic Lupus Erythematous | Recruiting | 2026-01-14 | 2028-12-01 | ClinicalTrials.gov |
| NCT06799247 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential… | Phase3 | Myasthaenia Gravis | Recruiting | 2025-05-06 | 2027-09-30 | ClinicalTrials.gov |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma | Phase1 | Refractory Multiple Myeloma | Terminated | 2024-06-19 | 2025-11-13 | ClinicalTrials.gov |
| NCT06038474 | Descartes-08 for Patients With Systemic Lupus Erythematosus | Phase2 | Systemic Lupus Erythematosus (SLE) | Active_Not_Recruiting | 2024-02-12 | 2027-12-01 | ClinicalTrials.gov |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myelom… | Phase2 | Myeloma Multiple | Terminated | 2021-12-01 | 2022-11-03 | ClinicalTrials.gov |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2021-11-25 | 2024-11-08 | ClinicalTrials.gov |
| NCT04436029 | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myelom… | Phase2 | Multiple Myeloma | Completed | 2021-02-24 | 2022-04-09 | ClinicalTrials.gov |
| NCT04524962 | Study of Descartes-30 in Acute Respiratory Distress Syndrome | Phase1 | Acute Respiratory Distress Syndrome | Terminated | 2021-02-23 | 2023-09-09 | ClinicalTrials.gov |
| NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | Phase2 | Myasthenia Gravis, Generalized | Active_Not_Recruiting | 2019-12-04 | 2026-03-31 | ClinicalTrials.gov |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2019-08-01 | 2021-06-11 | ClinicalTrials.gov |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | Phase1 | Multiple Myeloma | Terminated | 2018-03-08 | 2021-06-03 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03448978 |
| Fludarabine | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03448978 |
| Descartes-08 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03448978 |
| Descartes 08 | Other | Phase PHASE2 | Myeloma Multiple | TERMINATED | NCT04816526 |
| Descartes 30 | Other | Phase PHASE1 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04524962 |
| Descartes-25 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT05113342 |
| Descartes 11 | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT04436029 |
| Cyclophosphamide | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03994705 |
| Fludarabine | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03994705 |
| Descartes-11 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT03994705 |
| Descartes-08 | Other | Phase PHASE2 | Myasthenia Gravis, Generalized | ACTIVE_NOT_RECRUITING | NCT04146051 |
| Descartes-15 | Other | Phase PHASE1 | Refractory Multiple Myeloma | TERMINATED | NCT06304636 |
| Placebo Drug | Drug | Phase PHASE3 | Myasthaenia Gravis | RECRUITING | NCT06799247 |
| Decartes-08 | Other | Phase PHASE3 | Myasthaenia Gravis | RECRUITING | NCT06799247 |
| Descartes-08 | Other | Phase PHASE2 | Systemic Lupus Erythematosus (SLE) | ACTIVE_NOT_RECRUITING | NCT06038474 |
| Descartes-08 | Other | Phase PHASE1 | Childhood-onset Systemic Lupus Erythematous | RECRUITING | NCT07089121 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Placebo | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | Other | Phase PHASE2 | Antisynthetase Syndrome | RECRUITING | NCT07391605 |
| Descartes-08 | DRUG | Phase PHASE1 | Childhood-onset Systemic Lupus Erythematous | RECRUITING | NCT07089121 |